Valneva Stock: Shares Hit Resistance Following 2025 Revenue Announcement
Valneva has risen by 0.92% this Friday morning to 4.63 euros, following the announcement of its annual 2025 revenue. The stock has shown a sustained upward trend for several weeks, with a gain of more than 6.5% over seven days and nearly 24% over three months. This session occurs in a context of significant catalysts for the Franco-Austrian biotech company.
Valneva disclosed its preliminary results for fiscal year 2025 yesterday, reporting revenue of 174.7 million euros, consistent with the previous year's levels. The company also communicated an enhancement in its cash position, a critical element for a business in the advanced stage of clinical development. Attention is now turning to 2026, a year the laboratory has described as decisive. The initial Phase 3 results of its Lyme disease vaccine candidate, developed in partnership with Pfizer, are expected in the coming months. This program is the main potential growth driver for the group. The publication of the complete annual results is scheduled for March 16, followed by the first quarter results on May 7.
Technical Analysis of Valneva's Stock Price
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a technical standpoint, Valneva's stock price is precisely at its resistance level of 4.63 euros, which also corresponds to the upper Bollinger band at 4.66 euros. This technical confluence suggests that the stock is trading in the upper part of its recent channel, after having risen nearly 27% over a year. The Relative Strength Index (RSI), which measures the speed and magnitude of price movements, stands at 73, above the threshold of 70 generally considered as indicating an overbought zone. This reading reflects the intensity of the stock's recent upward movement. Concurrently, the price is significantly above its 50-day and 200-day moving averages, positioned at 4.03 and 3.67 euros respectively, confirming a well-established upward trend in the medium term. Whether or not the current resistance is breached will be a technical indicator to watch in the upcoming sessions.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
